• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Assertio Reports Third Quarter 2024 Financial Results

    11/11/24 4:02:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASRT alert in real time by email

    Third Quarter Total Net Product Sales of $28.7 Million

    Rolvedon Net Product Sales of $15.0 Million 

    Cash and Short-Term Investments of $88.6 Million

    LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024.

    "Third quarter results reflected solid performance as we continue to establish Rolvedon as our lead asset and drive economic returns from our commercial portfolio," said Brendan O'Grady, Chief Executive Officer. "Rolvedon has been well received by physicians, posting another quarter of stable performance and the continued expansion of our customer base. The Rolvedon same day dosing trial has concluded and the results have been accepted for presentation at the San Antonio Breast Cancer Symposium in December 2024."

    "Additionally, we have implemented new sales and marketing tactics for Sympazan, which are designed to drive prescriber awareness and prescription growth in key markets. We are maintaining our share of Indocin and working to maximize the value of this product and our other commercial assets moving forward. We are also evaluating new approaches to grow existing assets as well as the acquisition of additional assets to fuel further growth."

    Financial Highlights (unaudited):

     Three Months Ended Nine Months Ended
    (in millions, except per share amounts)September 30, 2024 June 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023
    Net Product Sales (GAAP)$28.7  $30.7  $35.1  $91.3  $117.0 
    Net Loss (GAAP)$(2.9) $(3.7) $(279.5) $(11.1) $(274.6)
    Loss Per Share (GAAP)$(0.03) $(0.04) $(3.42) $(0.12) $(4.35)
    Adjusted EBITDA (Non-GAAP)1$5.3  $5.0  $12.9  $17.7  $63.3 
    Adjusted Earnings Per Share (Non-GAAP)1$0.03  $0.02  $0.01  $0.09  $0.46 
                        

    Third quarter results included the following highlights (our discussion below focuses on a comparison of third quarter 2024 to second quarter 2024 given the acquisition of Spectrum and the generic competition of Indocin introduced in the third quarter 2023):

    • Rolvedon net product sales were stable at $15.0 million in the third quarter, from $15.1 million in the second quarter, driven by continued volume growth offset by lower net pricing. 
    • Indocin net product sales in the third quarter were $5.7 million, decreased from $6.9 million in the second quarter, due to the previously announced generic competition affecting pricing.
    • Gross margin2 in the third quarter increased to 74%, from 71% in the second quarter, primarily due a decrease in the level of inventory write downs in late life-cycle stage products and the completion of Rolvedon inventory step-up amortization.
    • SG&A expense in the third quarter was $16.7 million, decreased from $18.4 million in the second quarter. The decrease was primarily due to lower sales and marketing and other general and administrative costs, partially offset by net higher legal related charges.
    • Adjusted EBITDA3 was $5.3 million in the third quarter, increased from $5.0 million in the second quarter, primarily due to lower SG&A expense, partially offset by lower net product sales. 

    Balance Sheet and Cash Flow

    • For the quarter ended September 30, 2024, cash, cash equivalents and short-term investments were $88.6 million, compared with $88.4 million at June 30, 2024. Cash flow generation during the quarter was impacted by the timing of working capital as well as lower net product sales.
    • Debt at September 30, 2024 was $40.0 million, comprised of the Company's 6.5% convertible notes, with no maturities until September 2027.

    Board Updates

    Peter Staple retired from the board after more than 20 years as an independent director. Also, Dr. Jeffrey Vacirca has elected to depart from the board to focus on his other business interests. Both departures were effective November 7, 2024.

    Assertio announced the appointment of Heather Mason as Board Chair. Mason has served as an independent director since 2019 and as interim CEO of Assertio from January to May of 2024. Further, David Stark was appointed to the board as an independent director and member of the Nominating and Corporate Governance Committee. Stark was previously Executive Vice President and Chief Legal Officer at Teva Pharmaceutical Industries Limited.

    "I want thank Jeff and Peter for their service to Assertio and its shareholders," said Mason. "Jeff's insight into the oncology market since joining the board as part of the Spectrum transaction has been invaluable. Peter has served for more than 20 years on the Assertio board, offering calm leadership and wise counsel through transitions and challenges faced by the organization during his tenure. I also appreciate Peter extending his board service during the time of transition to Brendan O'Grady as the new CEO. I want to welcome David to the board and look forward to his partnership. David brings extensive litigation, compliance and acquisition experience from his time at Teva and earlier in private law firm practice."

    Conference Call and Investor Presentation Information

    Assertio's management will host a conference call to discuss its third quarter 2024 financial results today:

    Date:Monday, November 11, 2024
    Time:4:30 p.m. Eastern Time
    Webcast (live and archive):http://investor.assertiotx.com/overview/default.aspx

    (Events & Webcasts, Investor Page)
    Dial-in numbers:1-646-307-1963, Conference ID 3278948
      

    To access the live webcast, the recorded conference call replay, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. The replay will be available approximately two hours after the call on Assertio's investor website.

    1 Non-GAAP measures are reconciled to the corresponding GAAP measures in the schedules attached.

    2 Gross margin represents the ratio of net product sales less cost of sales to net product sales.

    3 See "Non-GAAP Financial Measures" below for information about reconciling our Adjusted EBITDA guidance to Net Loss.

    About Assertio

    Assertio is a commercial pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com.

    Investor Contact

    Matt Kreps, Managing Director

    Darrow Associates

    M: 214-597-8200

    [email protected]

    Forward Looking Statements

    The statements in this communication include forward-looking statements. Forward-looking statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs. Forward-looking statements speak only as of the date they are made or as of the dates indicated in the statements and should not be relied upon as predictions of future events, as there can be no assurance that the events or circumstances reflected in these statements will be achieved or will occur. Forward-looking statements can often, but not always, be identified by the use of forward-looking terminology such as "anticipate," "approximate", "believe," "could," "estimate," "expect," "goal," "intend," "may," "might," "opportunity," "plan," "potential," "project," "prospective," "pursue," "seek," "should," "strategy," "target," "will," or the negative of these words and phrases, other variations of these words and phrases or comparable terminology. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the statements, including: Assertio's ability to grow sales of, and the commercial success and market acceptance of, Rolvedon and Assertio's other products; Assertio's ability to successfully develop and execute its sales, marketing and promotion strategies using its sales force and non-personal promotion model capabilities; the impact on sales and profits from the entry and sales of generics of Assertio's products and/or other products competitive with any of Assertio's products (including indomethacin suppositories compounded by hospitals and other institutions including a 503B compounder which we believe to be violation of certain provisions of the Food, Drug and Cosmetic Act); the timing and impact of additional generic approvals and uncertainty around the recent approvals and launches of generic Indocin products (which are not patent protected and now face generic competition as a result of the August 2023 approval and launch of generic indomethacin suppositories and January 2024 approval and subsequent launch of a generic indomethacin oral suspension product); risks that any new businesses will not be integrated successfully or that the combined company will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer and/or cost more to realize than expected; expected industry trends, including pricing pressures and managed healthcare practices; Assertio's ability to attract and retain executive leadership and key employees; the ability of Assertio's third-party manufacturers to manufacture adequate quantities of commercially salable inventory and active pharmaceutical ingredients for each of Assertio's products on commercially reasonable terms and in compliance with their contractual obligations to Assertio, and Assertio's ability to maintain its supply chain which relies on single-source suppliers; the outcome of, and Assertio's intentions with respect to, any litigation or government investigations, including pending and potential future shareholder litigation relating to the Spectrum Merger and/or the recent approval and launch of generic indomethacin suppositories, opioid-related government investigations and opioid-related litigation, the recently unsealed qui tam litigation, as well as Spectrum's legacy shareholder and other litigation and, and other disputes and litigation, and the costs and expenses associated therewith; Assertio's financial cost and outcomes of clinical trials, including the extent to which data from the Rolvedon same-day dosing trial may support ongoing commercialization efforts; Assertio's compliance with legal and regulatory requirements related to the development or promotion of its products; variations in revenues obtained from commercialization agreements and the accounting treatment with respect thereto; Assertio's common stock maintaining compliance with The Nasdaq Capital Market's minimum closing bid requirement of at least $1.00 per share, particularly in light of Assertio's stock trading below or only slightly above $1.00 per share recently as well as recent market activity by a short seller; and Assertio's ability to obtain and maintain intellectual property protection for its products and operate its business without infringing the intellectual property rights of others. For a discussion of additional factors that could cause actual results to differ materially from those contemplated by forward-looking statements, see the risks described in Assertio's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Many of these risks and uncertainties may be exacerbated by public health emergencies and general macroeconomic conditions. Assertio does not assume, and hereby disclaims, any obligation to update forward-looking statements, except as may be required by law.

    Non-GAAP Financial Measures

    To supplement the Company's financial results presented on a U.S. generally accepted accounting principles ("GAAP") basis, the Company has included information about non-GAAP measures of EBITDA, adjusted EBITDA, adjusted earnings, and adjusted earnings per share as useful operating metrics. The Company believes that the presentation of these non-GAAP financial measures, when viewed with results under GAAP and the accompanying reconciliation, provides supplementary information to analysts, investors, lenders, and the Company's management in assessing the Company's performance and results from period to period. The Company uses these non-GAAP measures internally to understand, manage and evaluate the Company's performance, and in part, in the determination of bonuses for executive officers and employees. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

    Specified Items

    Non-GAAP measures presented within this release exclude specified items. The Company considers specified items to be significant income/expense items not indicative of current operations. Specified items may include adjustments to interest expense and interest income, income tax expense (benefit), depreciation expense, amortization expense, sales reserves adjustments for products the Company is no longer selling, stock-based compensation expense, fair value adjustments to contingent consideration or derivative liability, restructuring charges, amortization of fair value inventory step-up as a result of purchase accounting, transaction-related costs, gains, losses or impairments from adjustments to long-lived assets and assets not part of current operations, changes in valuation allowances on deferred tax assets, and gains or losses resulting from debt refinancing or extinguishment.

     
    CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

    (in thousands, except per share amounts)

    (unaudited)
        
     Three Months Ended Nine Months Ended
     September 30,

    2024
     June 30,

    2024
     September 30,

    2023
     September 30,

    2024
     September 30,

    2023
    Revenues:         
    Product sales, net$28,705  $30,695  $35,137  $91,262  $116,989 
    Royalties and milestones 499   431   490   1,516   1,910 
    Other revenue —   —   —   —   185 
    Total revenues 29,204   31,126   35,627   92,778   119,084 
    Costs and expenses:         
    Cost of sales 7,550   8,889   7,060   27,616   17,299 
    Research and development expenses 1,005   798   1,316   2,536   1,819 
    Selling, general and administrative expenses 16,726   18,385   21,005   53,635   54,680 
    Change in fair value of contingent consideration 300   —   (17,532)  300   (8,124)
    Amortization of intangible assets 6,671   6,671   10,184   18,973   22,752 
    Loss on impairment of intangible assets —   —   238,831   —   238,831 
    Restructuring charges —   —   3,034   720   3,034 
    Total costs and expenses 32,252   34,743   263,898   103,780   330,291 
    Loss from operations (3,048)  (3,617)  (228,271)  (11,002)  (211,207)
    Other income (expense):         
    Debt-related expenses —   —   —   —   (9,918)
    Interest expense (761)  (758)  (752)  (2,276)  (2,625)
    Interest income 887   842   605   2,441   1,713 
    Other gain (loss) 45   8   (467)  57   (112)
    Total other income (expense) 171   92   (614)  222   (10,942)
    Net loss before income taxes (2,877)  (3,525)  (228,885)  (10,780)  (222,149)
    Income tax expense (44)  (149)  (50,659)  (325)  (52,409)
    Net loss and comprehensive loss$(2,921) $(3,674) $(279,544) $(11,105) $(274,558)
              
    Basic net loss per share$(0.03) $(0.04) $(3.42) $(0.12) $(4.35)
    Diluted net loss per share$(0.03) $(0.04) $(3.42) $(0.12) $(4.35)
    Shares used in computing basic net loss per share 95,352   95,240   81,713   95,191   63,066 
    Shares used in computing diluted net loss per share 95,352   95,240   81,713   95,191   63,066 
                        



     
    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and per share data)
        
     (Unaudited)  
     September 30, 2024 December 31, 2023
    ASSETS   
    Current assets:   
    Cash and cash equivalents$37,981  $73,441 
    Short-term investments 50,598   — 
    Accounts receivable, net 44,944   47,663 
    Inventories, net 39,788   37,686 
    Prepaid and other current assets 7,845   12,272 
    Total current assets 181,156   171,062 
    Property and equipment, net 624   770 
    Intangible assets, net 92,359   111,332 
    Other long-term assets 1,860   3,255 
    Total assets$275,999  $286,419 
    LIABILITIES AND SHAREHOLDERS' EQUITY   
    Current liabilities:   
    Accounts payable$13,153  $13,439 
    Accrued rebates, returns and discounts 60,482   58,137 
    Accrued liabilities 12,964   18,213 
    Contingent consideration, current portion 3,000   2,700 
    Other current liabilities 505   954 
    Total current liabilities 90,104   93,443 
    Long-term debt 38,840   38,514 
    Other long-term liabilities 16,537   16,459 
    Total liabilities 145,481   148,416 
    Commitments and contingencies   
    Shareholders' equity:   
    Common stock, $0.0001 par value, 200,000,000 shares authorized; 95,360,756 and 94,668,523 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively. 9   9 
    Additional paid-in capital 793,157   789,537 
    Accumulated deficit (662,648)  (651,543)
    Total shareholders' equity 130,518   138,003 
    Total liabilities and shareholders' equity$275,999  $286,419 
            



     
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

    (unaudited)
      
     Nine Months Ended September 30,
     2024 2023
    Operating Activities   
    Net loss$(11,105) $(274,558)
    Adjustments to reconcile net loss to net cash from operating activities:   
    Depreciation and amortization 19,118   23,321 
    Amortization of debt issuance costs and Royalty Rights 326   350 
    Accretion of interest income from short-term investments (538)  — 
    Loss on impairment of intangible assets —   238,831 
    Recurring fair value measurements of assets and liabilities 269   (7,612)
    Debt-related expenses —   9,918 
    Provisions for inventory and other assets 4,982   2,129 
    Stock-based compensation 3,911   6,516 
    Deferred income taxes —   47,192 
    Changes in assets and liabilities, net of acquisition:   
    Accounts receivable 2,719   33,865 
    Inventories (7,084)  (8,898)
    Prepaid and other assets 5,822   6,769 
    Accounts payable and other accrued liabilities (5,255)  (21,523)
    Accrued rebates, returns and discounts 2,345   (11,027)
    Interest payable (650)  (1,376)
    Net cash provided by operating activities 14,860   43,897 
    Investing Activities   
    Purchases of property and equipment —   (528)
    Purchase of Sympazan —   (280)
    Net cash acquired in Spectrum Merger —   1,950 
    Proceeds from sale of short-term investments —   2,194 
    Proceeds from maturities of short-term investments 23,534   — 
    Purchases of short-term investments (73,563)  — 
    Net cash (used in) provided by investing activities (50,029)  3,336 
    Financing Activities   
    Payments in connection with 2027 Convertible Notes —   (10,500)
    Payment of direct transaction costs related to convertible debt inducement —   (1,119)
    Payment of contingent consideration —   (15,408)
    Payments related to the vesting and settlement of equity awards, net (291)  (7,770)
    Other financing activities —   (489)
    Net cash used in financing activities (291)  (35,286)
    Net (decrease) increase in cash and cash equivalents (35,460)  11,947 
    Cash and cash equivalents at beginning of year 73,441   64,941 
    Cash and cash equivalents at end of period$37,981  $76,888 
    Supplemental Disclosure of Cash Flow Information   
    Net cash paid for income taxes$1,388  $3,424 
    Cash paid for interest$2,600  $3,651 
            



     
    RECONCILIATION OF GAAP NET LOSS TO NON-GAAP EBITDA and ADJUSTED EBITDA

    (in thousands)

    (unaudited)
           
      Three Months Ended Nine Months Ended  
      September 30, 2024 June 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Financial Statement Classification
    GAAP Net Loss $(2,921) $(3,674) $(279,544) $(11,105) $(274,558)  
    Interest expense  761   758   752   2,276   2,625  Interest expense
    Income tax expense  44   149   50,659   325   52,409  Income tax expense
    Depreciation expense  40   40   172   145   569  Selling, general and administrative expenses
    Amortization of intangible assets  6,671   6,671   10,184   18,973   22,752  Amortization of intangible assets
    EBITDA (Non-GAAP) $4,595  $3,944  $(217,777) $10,614  $(196,203)  
    Adjustments:            
    Legacy product reserves  —   —   —   —   (185) Other revenue
    Stock-based compensation  1,296   1,408   1,864   3,911   6,516  Selling, general and administrative expenses
    Change in fair value of contingent consideration(1)  300   —   (17,532)  300   (8,124) Change in fair value of contingent consideration
    Debt-related expenses(2)  —   —   —   —   9,918  Debt-related expenses
    Transaction-related expenses(3)  —   —   2,736   —   8,539  Selling, general and administrative expenses
    Loss on impairment of intangible assets(4)  —   —   238,831   —   238,831  Loss on impairment of intangible assets
    Restructuring costs(5)  —   —   3,034   720   3,034  Restructuring charges
    Other(6)  (887)  (366)  1,755   2,123   967  Multiple
    Adjusted EBITDA (Non-GAAP) $5,304  $4,986  $12,911  $17,668  $63,293   



    (1) The fair value of the contingent consideration is remeasured each reporting period, with changes in the fair value resulting from changes in the underlying inputs being recognized as a benefit or expense in operating expenses until the contingent consideration arrangement is settled.



    (2) Debt-related expenses consist of an induced conversion expense of approximately $8.8 million and direct transaction costs of approximately $1.1 million incurred as a result of the privately negotiated exchange of $30.0 million principal amount of the Company's 6.5% Convertible Senior Notes due 2027 in the first quarter of 2023.



    (3) Represents transaction-related expenses associated with the acquisition of Spectrum, which closed effective July 31, 2023.



    (4) Represents the charge in the period for the impairment of intangible assets resulting from the revaluation of the Company's long-lived assets.



    (5) Restructuring costs represent non-recurring costs associated with the Company's announced restructuring plans.



    (6) Other for the three and nine months ended September 30, 2024 and 2023, and the three months ended June 30, 2024, represents the following adjustments (in thousands):



      Three Months Ended Nine Months Ended  
      September 30, 2024 June 30, 2024 September 30, 2023 September 30, 2024 September 30, 2023 Financial Statement Classification
    Amortization of inventory step-up $—  $476  $1,848  $4,564  $2,168  Cost of sales
    Interest income  (887)  (842)  (605)  (2,441)  (1,713) Interest income
    Derivative fair value adjustment  —   —   512   —   512  Other gain (loss)
    Total Other $(887) $(366) $1,755  $2,123  $967   
                           



     
    RECONCILIATION OF GAAP NET LOSS and NET LOSS PER SHARE TO

    NON-GAAP ADJUSTED EARNINGS and ADJUSTED EARNINGS PER SHARE(1)

    (in thousands, except per share amounts)

    (unaudited)
      
     Three Months Ended
     September 30, 2024 June 30, 2024 September 30, 2023
     Amount Diluted EPS(2) Amount Diluted EPS(2) Amount Diluted EPS(2)
    Net loss (GAAP)(2)$(2,921) $(0.03) $(3,674) $(0.04) $(279,544) $(3.42)
    Add: Convertible debt interest expense and other income statement impacts, net of tax(2) —     —     —   
    Adjustments:           
    Amortization of intangible assets 6,671     6,671     10,184   
    Stock-based compensation 1,296     1,408     1,864   
    Change in fair value of contingent consideration 300     —     (17,532)  
    Contingent consideration cash payable(3) (253)    —     (3,590)  
    Transaction-related expenses —     —     2,736   
    Loss on impairment of intangible assets(4) —     —     238,831   
    Restructuring costs —     —     3,034   
    Other (887)    (366)    1,755   
    Increase in deferred tax asset valuation allowance(5) —     —     43,035   
    Income tax benefit expense, as adjusted(6) (1,782)    (1,928)    387   
    Adjusted earnings (Non-GAAP)$2,424  $0.03  $2,111  $0.02  $1,160  $0.01 
                
    Diluted shares used in calculation (GAAP)(2) 95,352     95,240     81,713   
    Add: Dilutive effect of stock-based awards and equivalents(2) 933     394     2,191   
    Add: Dilutive effect of 2027 Convertible Notes(2) —     —     —   
    Diluted shares used in calculation (Non-GAAP)(2) 96,285     95,634     83,904   



    (1) Certain adjustments included here are the same as those reflected in the Company's reconciliation of GAAP net loss to non-GAAP adjusted EBITDA and therefore should be read in conjunction with that reconciliation and respective footnotes.



    (2) The Company uses the if-converted method with respect to its convertible debt to compute GAAP and Non-GAAP diluted earnings per share when the effect is dilutive. Under the if-converted method, the Company assumes the 2027 Convertible Notes were converted at the beginning of each period presented and outstanding. As a result, interest expense, net of tax, and any other income statement impact associated with the 2027 Convertible Notes, net of tax, is added back to net income used in the diluted earnings per share calculation.



      For the three months ended September 30, 2024, June 30, 2024, and September 30, 2023, the Company's potentially dilutive convertible debt under the if-converted method and stock-based awards under the treasury-stock method were not included in the computation of GAAP net loss and diluted net loss per share, and the potentially dilutive convertible debt under the if-converted method were not included in non-GAAP adjusted earnings and adjusted earnings per share, because to do so would be anti-dilutive.



      For the three months ended September 30, 2023, the Company's potentially dilutive convertible debt under the if-converted method was not included in the computation of both non-GAAP adjusted earnings per share and GAAP diluted net loss per share, because to do so would be anti-dilutive. However, the potentially dilutive stock-based awards under the treasury-stock method were included in the computation of non-GAAP adjusted earnings and adjusted earnings per share because the effect was dilutive.



    (3) Represents the accrued cash payable, if any, of the INDOCIN contingent consideration for the respective period based on 20% royalty for annual INDOCIN net sales over $20.0 million. 



    (4) Represents the charge in the period for the impairment of intangible assets resulting from the revaluation of the Company's long-lived assets.



    (5) Represents the amount of income tax expense related to the recognition of a full valuation allowance against deferred tax assets in the period.



    (6) Represents the Company's income tax expense adjustment from the tax effect of pre-tax adjustments excluded from adjusted earnings. The tax effect of pre-tax adjustments excluded from adjusted earnings is computed at the blended federal and state statutory rate of 25%.
       



     
    RECONCILIATION OF GAAP NET LOSS and NET LOSS PER SHARE TO

    NON-GAAP ADJUSTED EARNINGS and ADJUSTED EARNINGS PER SHARE(1)

    (in thousands, except per share amounts)

    (unaudited)
      
     Nine Months Ended
     September 30, 2024 September 30, 2023
     Amount Diluted EPS(2) Amount Diluted EPS(2)
    Net loss (GAAP)(2)$(11,105) $(0.12) $(274,558) $(4.35)
    Add: Convertible debt interest expense and other income statement impacts, net of tax(2) —     1,969   
    Adjustments:       
    Amortization of intangible assets 18,973     22,752   
    Legacy products revenue reserves —     (185)  
    Stock-based compensation 3,911     6,516   
    Debt-related expenses, net —     9,639   
    Change in fair value of contingent consideration 300     (8,124)  
    Contingent consideration cash payable(3) (253)    (11,274)  
    Transaction-related expenses —     8,539   
    Loss on impairment of intangible assets(4) —     238,831   
    Restructuring costs 720     3,034   
    Other 2,123     967   
    Increase in deferred tax asset valuation allowance(5) —     43,035   
    Income tax benefit expense, as adjusted(6) (6,444)    (5,556)  
    Adjusted earnings (Non-GAAP)$8,225  $0.09  $35,585  $0.46 
            
    Diluted shares used in calculation (GAAP)(2) 95,191     63,066   
    Add: Dilutive effect of stock-based awards and equivalents(2) 503     3,770   
    Add: Dilutive effect of 2027 Convertible Notes(2) —     11,324   
    Diluted shares used in calculation (Non-GAAP)(2) 95,694     78,160   



    (1) Certain adjustments included here are the same as those reflected in the Company's reconciliation of GAAP net loss to non-GAAP adjusted EBITDA and therefore should be read in conjunction with that reconciliation and respective footnotes.



    (2) The Company uses the if-converted method with respect to its convertible debt to compute GAAP and Non-GAAP diluted earnings per share when the effect is dilutive. Under the if-converted method, the Company assumes the 2027 Convertible Notes were converted at the beginning of each period presented and outstanding. As a result, interest expense, net of tax, and any other income statement impact associated with the 2027 Convertible Notes, net of tax, is added back to net income used in the diluted earnings per share calculation.



      For the nine months ended September 30, 2024, the Company's potentially dilutive convertible debt under the if-converted method and stock-based awards under the treasury-stock method were not included in the computation of GAAP net loss and diluted net loss per share, and the potentially dilutive convertible debt under the if-converted method were not included in non-GAAP adjusted earnings and adjusted earnings per share, because to do so would be anti-dilutive. However, the potentially dilutive stock-based awards under the treasury-stock method were included in the computation of non-GAAP adjusted earnings and adjusted earnings per share because the effect was dilutive.



      For the nine months ended September 30, 2023, the Company's potentially dilutive convertible debt under the if-converted method and stock-based awards under the treasury-stock method were not included in the computation of GAAP diluted net income per share, because to do so would be anti-dilutive. However, the potentially dilutive convertible debt under the if-converted method and stock-based awards under the treasury-stock method were included in the computation of non-GAAP adjusted earnings and adjusted earnings per share because the effect was dilutive.



    (3) Represents the accrued cash payable, if any, of the INDOCIN contingent consideration for the respective period based on 20% royalty for annual INDOCIN net sales over $20.0 million.



    (4) Represents the charge in the period for the impairment of intangible assets resulting from the revaluation of the Company's long-lived assets.



    (5) Represents the amount of income tax expense related to the recognition of a full valuation allowance against deferred tax assets in the period.



    (6) Represents the Company's income tax expense adjustment from the tax effect of pre-tax adjustments excluded from adjusted earnings. The tax effect of pre-tax adjustments excluded from adjusted earnings is computed at the blended federal and state statutory rate of 25%.
       


    Primary Logo

    Get the next $ASRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASRT

    DatePrice TargetRatingAnalyst
    7/26/2024$3.00Buy
    Maxim Group
    7/3/2024$4.00Buy
    H.C. Wainwright
    11/7/2022$7.00Buy
    Lake Street
    More analyst ratings

    $ASRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

      LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b

      12/17/24 8:30:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

      LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi

      12/12/24 8:00:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

      CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

      12/6/24 7:00:00 AM ET
      $ASRT
      $BEAM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

      SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

      11/14/24 3:52:50 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

      SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

      11/12/24 1:34:28 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

      SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

      11/4/24 11:29:13 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Financials

    Live finance-specific insights

    See more
    • Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

      LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

      5/5/25 8:15:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. Said Brendan O'Grady, Chief Executive Officer, "In line with our strategy for Assertio's long-term growth, 2024 was a year of stabilization as we transitioned to Rolvedon as our primary a

      3/12/25 4:05:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

      LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for a

      3/5/25 4:05:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel Schlessinger Sam converted options into 17,150 shares and covered exercise/tax liability with 7,656 shares, increasing direct ownership by 7% to 153,889 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      2/25/25 6:03:18 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Schwichtenberg Paul converted options into 17,150 shares and covered exercise/tax liability with 8,505 shares, increasing direct ownership by 6% to 146,345 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      2/25/25 6:02:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP and CFO Patel Ajay converted options into 17,150 shares and covered exercise/tax liability with 8,505 shares, increasing direct ownership by 5% to 175,675 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      2/25/25 6:00:12 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Assertio Holdings Inc.

      DEF 14A - Assertio Holdings, Inc. (0001808665) (Filer)

      4/8/25 4:40:37 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Assertio Holdings Inc.

      PRE 14A - Assertio Holdings, Inc. (0001808665) (Filer)

      3/25/25 5:24:21 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Assertio Holdings Inc.

      10-K - Assertio Holdings, Inc. (0001808665) (Filer)

      3/12/25 5:14:59 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

      LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

      5/5/25 8:15:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

      LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025. The Company will present at 1:30 pm Eastern Time on Tuesday, March 25, 2025. To join the presentation, please visit the webcast available online at https://investor.assertiotx.com/. Additionally, investors participating in the conference can request 1x1 meetings to take place on March 26, 2025 via their conference representative or through Assertio investor relations at [email protected]. T

      3/20/25 9:10:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. Said Brendan O'Grady, Chief Executive Officer, "In line with our strategy for Assertio's long-term growth, 2024 was a year of stabilization as we transitioned to Rolvedon as our primary a

      3/12/25 4:05:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      11/19/24 9:02:18 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      11/15/24 2:43:25 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      6/12/24 6:00:09 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

      Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

      6/10/24 1:20:50 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Assertio Therapeutics with a new price target

      Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00

      7/26/24 7:49:44 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Assertio Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00

      7/3/24 7:25:55 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Assertio Therapeutics with a new price target

      Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00

      11/7/22 9:24:08 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care